<div id="readability-page-1"><p>Edgewise Therapeutics, Inc. (NASDAQ:EWTX - Get Free Report) has been assigned a consensus recommendation of &#34;Moderate Buy&#34; from the eleven analysts that are  covering the firm, Marketbeat.com reports. One research analyst  has rated the stock with a sell recommendation, three have assigned  a hold recommendation, six have assigned  a buy recommendation and one  has issued  a strong buy recommendation on  the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $36.00.</p><div><p><span></span><span>Get <strong>Edgewise Therapeutics</strong> alerts:</span></p></div><ul><li>MarketBeat Week in Review – 9/23 - 9/27</li></ul><p>Several equities research analysts have issued reports on EWTX shares. Royal Bank Of Canada lifted their price target on Edgewise Therapeutics from $49.00 to $50.00 and gave the stock an &#34;outperform&#34; rating in a research note on Friday, November 7th. JPMorgan Chase &amp; Co. increased their price target on shares of Edgewise Therapeutics from $33.00 to $34.00 and gave the company an &#34;overweight&#34; rating in a research report on Friday, November 14th. Wedbush lowered their price objective on shares of Edgewise Therapeutics from $35.00 to $32.00 and set an &#34;outperform&#34; rating for the company in a report on Friday, November 7th. Wall Street Zen cut shares of Edgewise Therapeutics from a &#34;hold&#34; rating to a &#34;sell&#34; rating in a research report on Saturday. Finally, The Goldman Sachs Group started coverage on shares of Edgewise Therapeutics in a research note on Thursday, September 25th. They issued a &#34;neutral&#34; rating and a $20.00 price target for the company.</p><p><b>View Our Latest Stock Report on Edgewise Therapeutics</b></p><h2>Edgewise Therapeutics Price Performance</h2><ul><li>Analysts Think There's Still Time to Get in on Edgewise, Up 332%</li></ul><p>Shares of NASDAQ:EWTX opened at $26.35 on Friday. The company's fifty day moving average price is $21.30 and its 200-day moving average price is $16.77. The firm has a market capitalization of $2.79 billion, a price-to-earnings ratio of -16.68 and a beta of 0.26. Edgewise Therapeutics has a one year low of $10.60 and a one year high of $30.48. </p><p>Edgewise Therapeutics (NASDAQ:EWTX - Get Free Report) last posted its quarterly earnings data on Thursday, November 6th. The company reported ($0.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.40) by $0.01.  As a group, equities research analysts expect that  Edgewise Therapeutics will post -1.45 EPS for the current year. </p><h2>Insider Activity at Edgewise Therapeutics</h2><ul><li>Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge</li></ul><p>In related news, Director Jonathan C. Fox purchased 10,700 shares of the firm's stock in a transaction on Tuesday, November 11th. The shares were acquired at an average cost of $18.64 per share, with a total value of $199,448.00. Following the purchase, the director directly owned 23,702 shares of the company's stock, valued at approximately $441,805.28. This trade represents a 82.30% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Alan J. Russell sold 100,000 shares of the stock in a transaction that occurred on Wednesday, November 12th. The shares were sold at an average price of $21.12, for a total value of $2,112,000.00. Following the sale, the insider directly owned 23,400 shares of the company's stock, valued at approximately $494,208. This trade represents a 81.04% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 23.20% of the stock is owned by company insiders. </p><h2>Institutional Investors Weigh In On Edgewise Therapeutics</h2><p>Large investors have recently added to or reduced their stakes in the company. Bessemer Group Inc. raised its stake in shares of  Edgewise Therapeutics by 1,170.3% during the third quarter. Bessemer Group Inc. now owns 2,350 shares of the company's stock valued at $38,000 after acquiring an additional 2,165 shares during the last quarter.  Canada Pension Plan Investment Board purchased a new position in  Edgewise Therapeutics during the 2nd quarter valued at about $45,000.  Jones Financial Companies Lllp bought a new position in  Edgewise Therapeutics during the 1st quarter valued at approximately $47,000.  Mirae Asset Global Investments Co. Ltd. lifted its holdings in  Edgewise Therapeutics by 28.2% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,062 shares of the company's stock worth $53,000 after buying an additional 894 shares during the period.  Finally, Allostery Investments LP bought a new stake in shares of  Edgewise Therapeutics in the 1st quarter worth approximately $66,000. </p><h2>About Edgewise Therapeutics</h2> (Get Free Report)<p>Edgewise Therapeutics, Inc <span>NASDAQ: EWTX<span></span></span> is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.  </p><p>At the core of Edgewise's pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.</p><h2>Read More</h2><ul><li>Five stocks we like better than Edgewise Therapeutics</li><li>Do not delete, read immediately</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li><li>Can Any Expenses Be Deducted From Capital Gains Tax?</li><li>Do you know what Amazon is planning for January 1?</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVdUWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RVdUWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Edgewise Therapeutics Right Now?</h2><p>Before you consider Edgewise Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Edgewise Therapeutics wasn't on the list.</p><p>While Edgewise Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

EWTX

<p>Edgewise Therapeutics, Inc. (NASDAQ:EWTX) has received a consensus "Moderate Buy" rating from eleven analysts. The average 1-year price target is $36.00. Recent analyst actions include price target adjustments by Royal Bank Of Canada, JPMorgan Chase & Co., and Wedbush. Insider trading activities include significant stock purchases and sales. Institutional investors have adjusted their stakes in the company. Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on precision medicines.</p>

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) Receives Consensus Rating of "Moderate Buy" from Brokerages